1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Pfizer Fellowship Grant Program is sponsored by Pfizer Inc.. The Pfizer Fellowship Grant Program supports early-career researchers and clinicians who lead innovative work in priority health areas. The fellowship is meant for professionals who show strong academic achievement and a clear commitment to advancing healthcare solutions.
Priority research areas include oncology, infectious diseases and vaccines, inflammatory and immune-mediated conditions, and rare diseases and specialty care.
Get alerted about grants like this
Save a search for “Pfizer Inc.” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Competitive Grants Program | Pfizer Competitive Grants Program Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.
The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Inflammation & Immunology Support for the Professions British Indian Ocean Territory Congo, The Democratic Republic Falkland Islands (Malvinas) French Southern Territories Heard and Mc Donald Islands Holy See (Vatican City State) Iran (Islamic Republic of) Korea, Democratic People's Rep Lao People's Democratic Republ Macedonia, The Former Yugoslav Micronesia, Federated States o Saint Vincent and the Grenadin Slovakia (Slovak Republic) South Georgia and the South Sa Svalbard and Jan Mayen Islands Tanzania, United Republic of United States Minor Outlying I Wallis and Futuna Islands Optimizing Disease Management to Improve Alopecia Areata Quality of Care Release Date: January 15, 2026 Review Process: Pfizer Internal View RFP (PDF) Quality Improvement Inflammation & Immunology China April 30, 2026 Providing Appropriate Medical Care for IBD Patients Release Date: January 27, 2026 Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD) Review Process: Expert Review Panel View RFP (PDF) Quality Improvement Inflammation & Immunology Japan April 19, 2026 Advances in Migraine Management Release Date: February 11, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Internal Medicine USA May 8, 2026 Optimizing Atopic Dermatitis Quality of Care and Best Practice at Local Level Release Date: February 14, 2026 Review Process: Pfizer Internal View RFP (PDF) Quality Improvement Inflammation & Immunology China April 30, 2026 Efforts to Improve Quality of Migraine Care Release Date: March 4, 2026 Partner: The Japanese Headache Society Review Process: Expert Review Panel View RFP (PDF) Quality Improvement Internal Medicine Japan June 15, 2026 Enhancing HCP Education in Adult Vaccination against Respiratory Infections Release Date: March 5, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Vaccines Austria, Belgium, Greece, Ireland, Luxembourg, Portugal, Switzerland April 30, 2026 Migraine and Women’s Health Release Date: March 9, 2026 Partner: American Headache Society Review Process: Expert Review Panel View RFP (PDF) Quality Improvement, Research Internal Medicine USA May 5, 2026 Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid) Release Date: March 10, 2026 Review Process: Pfizer Internal View RFP (PDF) Research Rare Disease USA May 5, 2026 Capacity Building for Clinical Trials in Sickle Cell Disease (SCD) - Education for Healthcare Professionals Release Date: March 11, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Rare Disease USA May 5, 2026 Transthyretin Cardiac Amyloidosis Fellowship Release Date: March 12, 2026 Review Process: Expert Review Panel View RFP (PDF) Research Rare Disease USA May 6, 2026 Inflammation & Immunology Support for the Professions British Indian Ocean Territory Congo, The Democratic Republic Falkland Islands (Malvinas) French Southern Territories Heard and Mc Donald Islands Holy See (Vatican City State) Iran (Islamic Republic of) Korea, Democratic People's Rep Lao People's Democratic Republ Macedonia, The Former Yugoslav Micronesia, Federated States o Saint Vincent and the Grenadin Slovakia (Slovak Republic) South Georgia and the South Sa Svalbard and Jan Mayen Islands Tanzania, United Republic of United States Minor Outlying I Wallis and Futuna Islands Pneumococcal Disease Prevention Release Date: April 11, 2012 Review Process: View RFP (PDF) Release Date: May 8, 2012 Review Process: View RFP (PDF) Release Date: June 28, 2012 Review Process: View RFP (PDF) Pharmacy Pneumococcal Disease Prevention Release Date: June 28, 2012 Review Process: View RFP (PDF) Release Date: July 2, 2012 Review Process: View RFP (PDF) Non-Small Cell Lung Cancer Release Date: July 10, 2012 Review Process: View RFP (PDF) Cardiovascular Risk in Rheumatoid Arthritis Release Date: July 25, 2012 Review Process: View RFP (PDF) Release Date: July 26, 2012 Review Process: View RFP (PDF) Adult Pneumococcal Disease Prevention Release Date: August 29, 2012 Review Process: View RFP (PDF) Prevention of Stroke in Women Release Date: September 13, 2012 Review Process: View RFP (PDF) Oncology Educational Needs Assessments Release Date: October 22, 2012 Review Process: View RFP (PDF) Release Date: November 1, 2012 Review Process: View RFP (PDF)
According to the current listing, eligibility includes: Accredited institutions and individuals in eligible countries where Pfizer operates. The host institution must meet regulatory standards, and projects must comply with local and international research regulations. Applicants must meet professional licensing requirements where applicable. Confirm the full requirements in the official notice before applying.
The current listing shows USD 50,000 to USD 100,000 (up to $150,000 maximum). Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was May 15, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Pfizer Fellowship Grant Program is funded by Pfizer Inc.. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Pfizer Global Medical Grants: Antimicrobial Stewardship and AMR is a competitive grant program from Pfizer Inc. that funds independent initiatives — including research, quality improvement, and education — aimed at improving patient outcomes in antimicrobial stewardship and combating antimicrobial resistance (AMR). Pfizer publishes Requests for Proposals (RFPs) outlining specific gaps in research, practice, or care, and invites organizations to apply. Grantees are responsible for the design, implementation, and conduct of their initiatives. Eligible applicants include medical centers, universities, and healthcare organizations globally. Awards typically range from $50,000 to $250,000. Applications are reviewed on a rolling RFP basis — check Pfizer's grants portal for current open solicitations.
Competitive Grants Program (General RFP for independent initiatives) is a grant from Pfizer Inc. that funds arts projects and programming. Project Types and Area of Interest Potential applicants are encouraged to identify and address educational gaps relating to optimal application and management of targeted therapies for patients with mPC in diverse clinical practice settings. Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society). Eligible applicants include medical, scientific, patient, and civic organizations; healthcare institutions; professional associations; medical societies; medical education companies; and other healthcare-related entities.